

## **Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)**

TOKYO, JAPAN, October 26<sup>th</sup>, 2021 – Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiko Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”).

Darinaparsin is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma (PTCL). Solasia filed a new drug application with the Ministry of Health, Labour and Welfare in June 2021 and expects to launch after obtaining approval from the agency in 2022.

Mr. Kazuto Koizumi, Managing Director and Head of Pharmaceuticals Group of Nippon Kayaku, commented as follows:

“Solasia is a specialty pharmaceutical company that excels in development of innovative medicines in the field of oncology in Japan and other Asian countries. Through the early launch of darinaparsin developed by Solasia, we expect to provide a new treatment option for PTCL, and contribute to patients and their family suffering from the disease, as well as to healthcare professionals.”

Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:

“Nippon Kayaku is one of Japan's leading pharmaceutical companies with strengths in the field of oncology. We are very pleased to have this opportunity to deliver darinaparsin to nationwide medical institutions providing cancer treatment by utilizing Nippon Kayaku's extensive experience in oncology and strong sales network, and contribute to the treatment of PTCL.”

Based on this agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL, for which no standard treatment has been established to date.

###

### **About Nippon Kayaku**

Nippon Kayaku was founded in 1916 as the first industrial explosives manufacturer in Japan. We have developed products to meet the needs of the time by utilizing, combining and transforming our core technologies in the company's main areas, explosives, dyes, pharmaceuticals and resins. Nippon Kayaku has contributed to realizing a sustainable society through its four businesses of Functional Chemicals, Pharmaceuticals, Safety Systems, and Agrochemicals.

In the Pharmaceuticals Business, Nippon Kayaku specializes in anticancer drugs and other cancer-related products, handling a range of products from new drugs to biosimilars and generics. It strives to provide trustworthy information crucial for understanding anticancer drugs to medical institutions.

Please visit the company website at <https://www.nipponkayaku.co.jp/english/> for more information.

### **About Solasia**

Solasia is a specialty pharmaceutical company based in Asia, with a mission to provide “Better Medicine for a Brighter Tomorrow.” To address the unmet medical needs in the oncology field, Solasia develops innovative medicines to contribute to the better health and brighter future of patients.

Please visit the company website at <https://solasia.co.jp/en/> for more information.

### **About darinaparsin (SP-02)**

Darinaparsin, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. Darinaparsin is believed to exert anticancer effect by inducing cell cycle arrest and apoptosis. Darinaparsin has been

## NEWS RELEASE

granted orphan drug designation in the US and EU.

For more information, please visit at <https://solasia.co.jp/en/pipeline/sp02.html>

### **About peripheral T-cell lymphoma (PTCL)**

PTCL is a type of malignant lymphoma. Malignant lymphoma is largely classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), and non-Hodgkin lymphoma is further divided into two main categories of B-cell lymphoma and T-cell lymphoma. PTCL is a subtype of T-cell lymphoma with a relatively high incidence rate among other subtypes of T-cell lymphoma. No standard treatment has been established for PTCL, and the National Comprehensive Cancer Network guidelines recommend as front-line treatment participation in clinical trials or multidrug chemotherapy such as CHOP therapy. For relapsed or refractory PTCL patients, in addition to participation in clinical trials, multidrug chemotherapy or recently approved drugs are recommended. However, as with the newly diagnosed cases, no standard therapy has been established. As prognosis for PTCL may be poor and its treatment difficult, it is one of the diseases with high unmet medical needs for which the development and introduction of new therapies and drugs are much anticipated.

### **For further information, please contact:**

#### **Nippon Kayaku Co., Ltd.**

Public Relations & Investor Relations Division,  
Tel. +81 3 6731 5237

#### **Solasia Pharma K.K.**

Rie Toyoda, Public Relations and Investor Relations,  
Tel. +81 3 5843 8045

[info@solasia.co.jp](mailto:info@solasia.co.jp)